<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254189</url>
  </required_header>
  <id_info>
    <org_study_id>0858A2-208</org_study_id>
    <nct_id>NCT00254189</nct_id>
  </id_info>
  <brief_title>Study Evaluating Effects of Levonorgestrel and Ethinyl Estradiol on Ovulation</brief_title>
  <official_title>A Single Center, Open-Label Study to Evaluate the Effects on Ovulation of Levonorgestrel 90mg and Ethinyl Estradiol 20mg in a Daily, Continuous, Oral Regimen.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To determine the ability of a monophasic oral contraceptives (&quot;OC&quot;) regimen of Levonorgestrel
      (&quot;LNG&quot;) 90 mg and Ethinyl Estradiol (&quot;EE&quot;) 20 mg to inhibit ovulation during 84 days of
      continuous therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date>October 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the ability of a monophasic oral contraceptive (OC) regimen of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg to inhibit ovulation during 84 days of continuous therapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety profile. To assess the ovarian activity, as measured by the Hoogland and Skouby 6-point grading system, during 84 days of continuous therapy. To evaluate the time to return of ovulation after cessation of treatment.</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Ovulation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl Estradiol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women of legal age of consent who are willing to use a combination OC.

          -  Subjects must be under the age of 36 at the time of enrollment (visit 3).

          -  Subjects must have had regular (24 to 32 day) menstrual cycles for the 3-month period
             preceding entry into the pretreatment observation cycle, excluding postabortal and
             nonnursing postpartum subjects. Postabortal and nonnursing postpartum subjects must
             have completed at least 1 regular (24 to 32 day) spontaneous menstrual cycle before
             entry into the pretreatment observation cycle. The pretreatment observation cycle for
             all subjects will begin on day 1 of the subsequent spontaneous menses.

        Other inclusions apply.

        Exclusion Criteria:

        A history or the presence of any of the following will prevent enrollment:

          -  Thrombophlebitis, thrombosis, or thromboembolic disorders.

          -  Deep vein thrombosis.

          -  Pulmonary embolism.

        Other exclusions apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>May 17, 2006</last_update_submitted>
  <last_update_submitted_qc>May 17, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2006</last_update_posted>
  <keyword>Ovulation</keyword>
  <keyword>Oral Contraceptive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

